daunorubicin has been researched along with Hypokalemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ben-Am, M; Burnett, A; Capdeville, R; Dekker, A; Ferrant, C; Gratwohl, A; Kovacsovics, T; Löwenberg, B; Ossenkoppele, G; Pfister, C; Rosenkranz, G; Sonneveld, P; Vellenga, E; Verhoef, G; Vossebeld, P; Yin, L | 1 |
| Brun, B; Dreyfus, B; Imbert, M; Reyes, F; Rochant, H; Sultan, C; Tulliez, M; Vernant, JP | 1 |
1 trial(s) available for daunorubicin and Hypokalemia
| Article | Year |
|---|---|
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cohort Studies; Cyclosporins; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Edema; Female; Fever; Humans; Hypokalemia; Leukemia, Myeloid; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasm Proteins; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome | 2000 |
1 other study(ies) available for daunorubicin and Hypokalemia
| Article | Year |
|---|---|
[Acute monoblastic leukemia. Clinical and therapeutic aspects in 20 cases].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Female; Gingiva; Humans; Hypokalemia; Leukemia, Monocytic, Acute; Male; Middle Aged; Muramidase; Potassium; Splenomegaly | 1976 |